Hub : Traits :

Medication: Allopurinol

187 significantly associated models · 46 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	26592429	28607344	13	1	3.8e-24	3.6e-24	0.0684	97	FNDC4
2	4	9370814	11156010	4	10	2.8e-56	4.2e-69	NaN	NaN	RP11-448G15.3 SLC2A9 WDR1
3	4	87655053	89898476	6	12	8.8e-117	5.7e-174	NaN	NaN	ABCG2 HERC6 NUDT9 PKD2 PPM1K SPP1
4	6	25266147	26689223	2	1	1.0e-10	1.1e-12	0.0023	82	U91328.21
5	7	72674074	73738067	1	1	3.3e-08	1.9e-08	1.0000	100	MLXIPL
6	10	60712592	62185494	1	1	2.5e-07	6.2e-09	0.0073	79	SLC16A9
7	11	63305184	66262606	5	7	5.6e-18	2.4e-15	NaN	NaN	NRXN2 OVOL1 SLC22A11 SLC22A12 VEGFB
8	12	57249600	58677299	2	1	7.9e-10	3.1e-11	0.0114	86	INHBC
9	12	121820692	123326374	1	1	3.0e-09	9.7e-10	0.0918	92	MLXIP
10	15	75444033	76878362	1	1	4.5e-09	6.2e-07	0.2150	94	UBE2Q2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	0.98	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder or Schizophrenia	0.92	1	0	0.0	0.00	1.0e+00	U91328.21
Intelligence (Savage-Jansen 2018)	0.68	1	0	0.0	0.00	1.0e+00	INHBC
Schizophrenia vs Biploar Disorder	1.32	1	0	0.0	0.00	1.0e+00	FNDC4
Worry (Nagel 2018)	0.72	1	0	0.0	0.00	1.0e+00	PKD2
Crohns Disease (2017)	1.21	1	1	2.2	0.00	1.0e+00	FNDC4
Irritable Bowel Disease (IBD)	0.84	1	1	2.2	0.00	1.0e+00	FNDC4
Breast Cancer	2.63	2	1	2.2	0.94	1.7e-02	ABCG2 PPM1K
Body Mass Index (BMI) (2010)	1.78	1	0	0.0	0.00	1.0e+00	MLXIP
Crohns Disease (2012)	1.15	1	0	0.0	0.00	1.0e+00	FNDC4
Fasting Glucose	3.18	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	1.65	2	1	2.2	0.00	1.0e+00	INHBC MLXIPL
LDL Cholesterol	1.24	2	0	0.0	0.00	1.0e+00	FNDC4 OVOL1
Triglycerides	16.21	3	3	6.7	0.00	1.0e+00	FNDC4 INHBC MLXIPL
Blood Eosinophil Count	0.80	2	1	2.2	0.00	1.0e+00	MLXIPL OVOL1
Blood Platelet Count	2.06	8	5	11.1	0.72	4.3e-02	FNDC4 INHBC MLXIP MLXIPL NUDT9 OVOL1 SLC2A9 UBE2Q2
Blood Red Count	0.99	5	3	6.7	-0.21	7.3e-01	FNDC4 INHBC MLXIP RP11-448G15.3 UBE2Q2
Blood White Count	1.90	4	2	4.4	0.90	9.8e-02	FNDC4 MLXIPL RP11-448G15.3 SLC16A9
Heel T-Score	1.92	6	4	8.9	0.69	8.5e-02	ABCG2 OVOL1 PKD2 PPM1K SLC16A9 SPP1
BMI	2.02	8	7	15.6	-0.80	5.9e-03	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 PPM1K SLC22A12 SLC2A9
Height	1.03	8	6	13.3	-0.76	2.9e-02	FNDC4 MLXIP MLXIPL NUDT9 OVOL1 SLC16A9 SLC2A9 SPP1
Waist Hip Ratio (WHR)	0.95	2	1	2.2	0.00	1.0e+00	MLXIP MLXIPL
Systolic Blood Pressure	1.05	5	0	0.0	0.97	6.1e-03	FNDC4 MLXIP NRXN2 OVOL1 SLC16A9
Smoking Status	0.97	1	0	0.0	0.00	1.0e+00	NRXN2
Allergy or Eczema	1.36	3	1	2.2	0.00	1.0e+00	FNDC4 MLXIP OVOL1
Cardiovascular Disease	1.24	3	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL OVOL1
Hypothyroidism (self reported)	1.58	2	0	0.0	0.00	1.0e+00	MLXIP PKD2
Type 2 Diabetes (T2D) (2018)	1.68	1	1	2.2	0.00	1.0e+00	FNDC4
Lung FEV1/FVC ratio	0.38	1	0	0.0	0.00	1.0e+00	SLC2A9
Lung FVC	0.65	1	0	0.0	0.00	1.0e+00	FNDC4
Hair Pigment	0.13	4	0	0.0	0.28	7.2e-01	FNDC4 INHBC MLXIPL OVOL1
Tanning	0.29	2	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL
Number of treatments/medications taken	1.41	2	0	0.0	0.00	1.0e+00	FNDC4 OVOL1
Sensitivity / hurt feelings	0.79	1	0	0.0	0.00	1.0e+00	U91328.21
Relative age of first facial hair	1.39	2	1	2.2	0.00	1.0e+00	FNDC4 OVOL1
Medication: Metformin	1.03	1	1	2.2	0.00	1.0e+00	FNDC4
Diabetes (father)	1.15	1	0	0.0	0.00	1.0e+00	FNDC4
Diabetes (mother)	1.53	1	0	0.0	0.00	1.0e+00	FNDC4
Impedance of leg (right)	1.67	5	2	4.4	0.90	3.7e-02	FNDC4 MLXIP MLXIPL PPM1K SPP1
Leg fat-free mass (left)	2.18	7	3	6.7	-0.88	8.9e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat percentage	0.95	2	1	2.2	0.00	1.0e+00	MLXIP NRXN2
Hand grip strength (right)	0.78	1	0	0.0	0.00	1.0e+00	FNDC4
Heel bone mineral density (BMD) T-score, automated (left)	1.59	4	1	2.2	0.99	7.6e-03	OVOL1 PKD2 PPM1K SPP1
High blood pressure	0.93	1	0	0.0	0.00	1.0e+00	OVOL1
Hayfever, allergic rhinitis or eczema	1.55	2	1	2.2	0.00	1.0e+00	OVOL1 U91328.21
Sitting height	1.62	6	5	11.1	-0.45	3.7e-01	FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Body mass index (BMI)	1.76	7	1	2.2	-0.88	4.0e-03	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 PPM1K SLC22A12
Impedance of leg (left)	1.83	6	3	6.7	0.68	1.3e-01	FNDC4 MLXIP MLXIPL PPM1K SLC2A9 SPP1
Leg predicted mass (left)	2.18	7	3	6.7	-0.88	9.0e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Trunk fat mass	1.30	3	1	2.2	-0.73	2.7e-01	ABCG2 MLXIP NRXN2
Waist circumference	1.53	5	1	2.2	-0.91	3.4e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K
Forced vital capacity (FVC)	0.80	2	0	0.0	0.00	1.0e+00	PKD2 PPM1K
Heel bone mineral density (BMD) T-score, automated (right)	1.51	4	1	2.2	0.98	1.8e-02	OVOL1 PKD2 PPM1K SPP1
Heart attack	1.02	1	0	0.0	0.00	1.0e+00	INHBC
Allergy	1.20	2	1	2.2	0.00	1.0e+00	INHBC OVOL1
Diabetes (self-reported)	1.55	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Simvastatin	1.71	1	1	2.2	0.00	1.0e+00	FNDC4
Weight	1.98	6	3	6.7	-0.87	1.0e-02	ABCG2 FNDC4 MLXIP MLXIPL NRXN2 U91328.21
Impedance of arm (right)	2.10	3	2	4.4	0.00	1.0e+00	FNDC4 MLXIPL SLC2A9
Arm fat percentage (right)	1.16	4	1	2.2	-0.81	9.6e-02	ABCG2 MLXIP NRXN2 PPM1K
Trunk fat-free mass	2.38	7	5	11.1	-0.88	9.9e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Hip circumference	2.24	5	3	6.7	-0.78	6.5e-02	ABCG2 FNDC4 MLXIP MLXIPL NRXN2
Alcohol intake versus 10 years previously	2.09	1	1	2.2	0.00	1.0e+00	FNDC4
Forced expiratory volume in 1-second (FEV1)	0.77	2	0	0.0	0.00	1.0e+00	PKD2 PPM1K
Pulse rate	1.21	1	1	2.2	0.00	1.0e+00	FNDC4
Serious illness, injury or assault of a close relative in last 2 years	1.59	1	0	0.0	0.00	1.0e+00	NRXN2
Asthma	0.78	1	0	0.0	0.00	1.0e+00	U91328.21
Medication: Cholesterol lowering	1.84	1	1	2.2	0.00	1.0e+00	FNDC4
Forced expiratory volume in 1-second (FEV1), Best measure	0.76	1	0	0.0	0.00	1.0e+00	U91328.21
Impedance of arm (left)	2.25	4	2	4.4	0.90	1.0e-01	FNDC4 MLXIPL SLC22A12 SLC2A9
Arm fat mass (right)	1.58	5	1	2.2	-0.84	3.6e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K
Trunk predicted mass	2.38	7	5	11.1	-0.87	1.1e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Standing height	1.26	8	4	8.9	-0.48	2.3e-01	FNDC4 MLXIP NUDT9 SLC16A9 SLC22A11 SLC2A9 SPP1 U91328.21
Headache pain in last month	1.04	1	0	0.0	0.00	1.0e+00	NUDT9
Medication for cholesterol, blood pressure or diabetes	1.05	1	0	0.0	0.00	1.0e+00	FNDC4
Gout (self-reported)	65.20	21	21	46.7	1.00	1.3e-39	ABCG2 FNDC4 HERC6 INHBC MLXIP MLXIPL NRXN2 NUDT9 OVOL1 PKD2 PPM1K RP11-448G15.3 SLC16A9 SLC22A11 SLC22A12 SLC2A9 SPP1 U91328.21 UBE2Q2 VEGFB WDR1
Medication: Amlodipine	1.19	1	0	0.0	0.00	1.0e+00	OVOL1
High blood pressure (siblings)	1.03	1	0	0.0	0.00	1.0e+00	FNDC4
Forced vital capacity (FVC), Best measure	0.89	1	0	0.0	0.00	1.0e+00	SLC16A9
Body fat percentage	1.07	4	1	2.2	-0.79	1.1e-01	ABCG2 MLXIP NRXN2 PPM1K
Leg fat percentage (right)	1.41	5	1	2.2	-0.80	5.6e-02	ABCG2 MLXIP NRXN2 PPM1K SLC22A12
Arm fat-free mass (right)	2.46	7	4	8.9	-0.87	1.1e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Comparative body size at age 10	1.07	2	0	0.0	0.00	1.0e+00	MLXIP OVOL1
Whole body fat mass	1.50	4	1	2.2	-0.80	1.0e-01	ABCG2 MLXIP NRXN2 PPM1K
Leg fat mass (right)	1.73	6	1	2.2	-0.85	1.5e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K SLC22A12
Arm predicted mass (right)	2.44	7	4	8.9	-0.86	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Pulse rate, automated reading	1.87	2	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL
Alcohol intake frequency.	3.01	3	1	2.2	0.00	1.0e+00	FNDC4 MLXIPL UBE2Q2
Comparative height size at age 10	1.36	5	3	6.7	-0.98	2.7e-03	FNDC4 MLXIP SLC16A9 SLC2A9 U91328.21
Hypertension (Self-reported)	0.91	1	0	0.0	0.00	1.0e+00	OVOL1
Forced expiratory volume in 1-second (FEV1), predicted	0.81	1	0	0.0	0.00	1.0e+00	SLC16A9
Whole body fat-free mass	2.33	7	4	8.9	-0.87	1.0e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat-free mass (right)	2.07	7	3	6.7	-0.88	9.4e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat percentage (left)	1.27	4	1	2.2	-0.82	9.0e-02	ABCG2 MLXIP NRXN2 PPM1K
Diabetes diagnosed by doctor	1.65	1	1	2.2	0.00	1.0e+00	FNDC4
Medication for cholesterol	1.43	1	1	2.2	0.00	1.0e+00	FNDC4
Back pain experienced in last month	1.20	1	0	0.0	0.00	1.0e+00	NUDT9
Osteoporosis (self-reported)	1.49	1	0	0.0	0.00	1.0e+00	SPP1
Whole body water mass	2.36	7	4	8.9	-0.87	1.1e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg predicted mass (right)	2.06	7	3	6.7	-0.88	9.3e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Arm fat mass (left)	1.63	5	1	2.2	-0.84	3.5e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K
Number of self-reported non-cancer illnesses	1.65	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Blood pressure	1.55	1	0	0.0	0.00	1.0e+00	OVOL1
Pain type(s) experienced in last month: Hip pain	2.42	1	0	0.0	0.00	1.0e+00	MLXIP
High cholesterol (Self-reported)	3.87	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Bendroflumethiazide	1.34	1	0	0.0	0.00	1.0e+00	NUDT9
Medication: Lisinopril	1.11	1	0	0.0	0.00	1.0e+00	MLXIP
Medication: Atorvastatin	2.49	1	1	2.2	0.00	1.0e+00	FNDC4
Ever smoked	1.95	2	0	0.0	0.00	1.0e+00	NRXN2 SLC22A12
Basal metabolic rate	2.26	7	4	8.9	-0.89	7.2e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Leg fat percentage (left)	1.31	5	0	0.0	-0.80	5.4e-02	ABCG2 MLXIP NRXN2 PPM1K SLC22A12
Arm fat-free mass (left)	2.30	7	4	8.9	-0.87	1.2e-02	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21
Diastolic blood pressure, automated reading	0.64	1	0	0.0	0.00	1.0e+00	OVOL1
Vascular/heart problems diagnosed by doctor	0.90	1	0	0.0	0.00	1.0e+00	OVOL1
Cholesterol lowering medication	2.04	1	1	2.2	0.00	1.0e+00	FNDC4
Heart attack/myocardial infarction (self-reported)	1.08	1	0	0.0	0.00	1.0e+00	INHBC
Impedance of whole body	2.19	6	2	4.4	0.77	7.5e-02	ABCG2 FNDC4 MLXIPL PPM1K SLC2A9 SPP1
Leg fat mass (left)	1.71	5	1	2.2	-0.85	3.1e-02	ABCG2 FNDC4 MLXIP NRXN2 PPM1K
Arm predicted mass (left)	2.38	7	4	8.9	-0.88	8.8e-03	ABCG2 FNDC4 MLXIP MLXIPL NUDT9 SLC16A9 U91328.21

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	7	0.201	1.4
GTEx	Adipose Visceral Omentum	6	0.295	1.6
GTEx	Adrenal Gland	3	0.206	1.4
GTEx	Artery Aorta	4	0.134	1.3
GTEx	Artery Coronary	2	0.169	1.4
GTEx	Artery Tibial	8	0.213	1.4
GTEx	Brain Caudate basal ganglia	0	0.000	1.2
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.4
GTEx	Brain Cerebellum	1	0.050	1.3
GTEx	Brain Cortex	0	0.000	1.3
GTEx	Brain Frontal Cortex BA9	0	0.000	1.3
GTEx	Brain Hippocampus	0	0.000	1.2
GTEx	Brain Hypothalamus	0	0.000	1.3
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	2	0.101	1.4
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.3
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.3
GTEx	Cells EBV-transformed lymphocytes	1	0.070	1.3
GTEx	Cells Transformed fibroblasts	6	0.143	1.3
GTEx	Colon Sigmoid	3	0.205	1.5
GTEx	Colon Transverse	4	0.194	1.4
GTEx	Esophagus Gastroesophageal Junction	1	0.069	1.3
GTEx	Esophagus Mucosa	4	0.120	1.3
GTEx	Esophagus Muscularis	6	0.186	1.4
GTEx	Heart Atrial Appendage	1	0.063	1.2
GTEx	Heart Left Ventricle	0	0.000	1.3
GTEx	Liver	1	0.139	1.4
GTEx	Lung	2	0.070	1.3
GTEx	Muscle Skeletal	5	0.173	1.3
GTEx	Nerve Tibial	9	0.208	1.4
GTEx	Ovary	2	0.220	1.4
GTEx	Pancreas	3	0.184	1.4
GTEx	Pituitary	1	0.090	1.3
GTEx	Prostate	0	0.000	1.4
GTEx	Skin Not Sun Exposed Suprapubic	3	0.122	1.3
GTEx	Skin Sun Exposed Lower leg	4	0.110	1.3
GTEx	Small Intestine Terminal Ileum	1	0.217	1.5
GTEx	Spleen	1	0.071	1.4
GTEx	Stomach	0	0.000	1.3
GTEx	Testis	4	0.127	1.4
GTEx	Thyroid	6	0.150	1.4
GTEx	Uterus	0	0.000	1.3
GTEx	Vagina	1	0.157	1.3
GTEx	Whole Blood	4	0.201	1.4
METSIM	Adipose	6	0.130	1.3
NTR	Blood	1	0.042	1.3
ROSMAP	Brain Pre-frontal Cortex	8	0.182	1.3
YFS	Blood	2	0.043	1.3
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	7	0.159	1.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.2
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.4
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	7	0.171	1.4
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	3	0.070	1.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	1	0.034	1.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	6	0.130	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.3
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	2	0.119	1.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	1	0.078	1.3
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.3